| Management target | Revenue FY27 |
|---|
| Revenue growth | 39.7% YoY; 6% QoQ growth. Strongest Q1 in 4 years. |
|---|---|
| Margins | Sequential EBITDA margin at 16.9%; targeting 19-20% by Q4 FY27. |
| Order book | Robust; 105 active clients. Large tectonic deals ramping up. |
| Demand visibility | Positive; clients excited by AI, though enterprise adoption remains measured. |
| Management confidence | Confident, shifting from optimism to conviction regarding GenAI and scale. |
Growth
Revenue grew 39.7% YoY; 6% QoQ. Growth is high-quality, driven by accounts beyond top 20.
Outlook
EBITDA margins expected to return to 19-20% by Q4 FY27 as revenue scales.
Risks
Margins are under pressure from upfront tectonic deal costs and workforce transformation expenses.
Last quarter's promises, checked
Delivered
- Revenue ₹3,500cr+ FY26 → ₹35,105M (= BEAT)
- Q4 Revenue ₹1,000cr+ → ₹10,000M (= BEAT)
- Active customers 73 to 91 → 105 (= BEAT)
Partly delivered
- DSO 63 days → 60s to 70s guidance (= PARTIAL)
Missed
- EBITDA margin 19-20% → 16.9% (= MISS)
Earnings Call Transcript filed with BSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹608.95
- Market cap
- ₹14,670 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.6×Sector 57.8×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Investor Presentation: Key Takeaways
Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.
Indegene Q1 FY27 Results: Net Profit ₹116.2 Cr, Down 0.2% YoY
Indegene Ltd reported revenue from operations of ₹1,063 Cr (+39.7% YoY) and net profit of ₹116.2 Cr (-0.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹116.2 Cr · -0.2% YoY
Indegene Earnings Call: Key Takeaways
Indegene reported FY26 revenue of INR 35,105M with 19.4% adjusted EBITDA margin, positioning itself as an AI-embedded specialist displacing traditional agencies and CROs in life sciences.
Indegene Earnings Call: Key Takeaways
Indegene positions as an AI-embedded operating partner for life sciences. Reported FY26 revenue of INR 35.1Bn with 19.4% EBITDA margins and 29.4% CAGR.